Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 119

1.

To treat or not to treat: Sequential individualized treatment evaluation in relapsing multiple sclerosis.

Bsteh G, Hegen H, Dosser C, Auer M, Berek K, Wurth S, Zinganell A, Di Pauli F, Deisenhammer F, Berger T.

Mult Scler Relat Disord. 2019 Dec 23;39:101908. doi: 10.1016/j.msard.2019.101908. [Epub ahead of print]

PMID:
31896060
2.

Serum neurofilament light levels correlate with change of olfactory function in multiple sclerosis.

Bsteh G, Berek K, Hegen H, Buchmann A, Voortman MM, Auer M, Wurth S, Zinganell A, Di Pauli F, Deisenhammer F, Khalil M, Berger T.

Mult Scler J Exp Transl Clin. 2019 Nov 5;5(4):2055217319885987. doi: 10.1177/2055217319885987. eCollection 2019 Oct-Dec.

3.

Serum hepcidin levels in multiple sclerosis.

Bsteh G, Haschka D, Tymoszuk P, Berek K, Petzer V, Hegen H, Wurth S, Auer M, Zinganell A, Pauli FD, Deisenhammer F, Weiss G, Berger T.

Mult Scler J Exp Transl Clin. 2019 Nov 4;5(4):2055217319885984. doi: 10.1177/2055217319885984. eCollection 2019 Oct-Dec.

4.

Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis.

Bsteh G, Berek K, Hegen H, Teuchner B, Buchmann A, Voortman MM, Auer M, Wurth S, Zinganell A, Di Pauli F, Deisenhammer F, Khalil M, Berger T.

Mult Scler. 2019 Oct 31:1352458519882279. doi: 10.1177/1352458519882279. [Epub ahead of print]

PMID:
31668116
5.

Interferon-β corrects massive gene dysregulation in multiple sclerosis: Short-term and long-term effects on immune regulation and neuroprotection.

Feng X, Bao R, Li L, Deisenhammer F, Arnason BGW, Reder AT.

EBioMedicine. 2019 Nov;49:269-283. doi: 10.1016/j.ebiom.2019.09.059. Epub 2019 Oct 21.

6.

A single T cell epitope drives the neutralizing anti-drug antibody response to natalizumab in multiple sclerosis patients.

Cassotta A, Mikol V, Bertrand T, Pouzieux S, Le Parc J, Ferrari P, Dumas J, Auer M, Deisenhammer F, Gastaldi M, Franciotta D, Silacci-Fregni C, Fernandez Rodriguez B, Giacchetto-Sasselli I, Foglierini M, Jarrossay D, Geiger R, Sallusto F, Lanzavecchia A, Piccoli L.

Nat Med. 2019 Sep;25(9):1402-1407. doi: 10.1038/s41591-019-0568-2. Epub 2019 Sep 9.

PMID:
31501610
7.

Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.

Schwab N, Schneider-Hohendorf T, Pignolet B, Bucciarelli F, Scandella L, Ciron J, Biotti D, Lebrun-Frenay C, Mathey G, Clavelou P, Pelletier J, Ostkamp P, Meinl I, Windhagen S, Klotz L, Gross CC, Meuth SG, Deisenhammer F, Brassat D, Wiendl H; Best-MS Study Group.

Neurology. 2019 Sep 17;93(12):550-554. doi: 10.1212/WNL.0000000000008135. Epub 2019 Aug 22. No abstract available.

PMID:
31439633
8.

German translation, cultural adaption and validation of the unidimensional self-efficacy scale for multiple sclerosis: a study protocol.

Seebacher B, Mills RJ, Reindl M, Zamarian L, Kuisma R, Kircher S, Brenneis C, Ehling R, Deisenhammer F.

BMJ Open. 2019 Aug 20;9(8):e029565. doi: 10.1136/bmjopen-2019-029565.

9.

Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases.

Hofer LS, Mariotto S, Wurth S, Ferrari S, Mancinelli CR, Delogu R, Monaco S, Gajofatto A, Schwaiger C, Rostasy K, Deisenhammer F, Höftberger R, Berger T, Reindl M.

Mult Scler J Exp Transl Clin. 2019 May 15;5(2):2055217319848463. doi: 10.1177/2055217319848463. eCollection 2019 Apr-Jun.

10.

Dataset for worldwide survey of cerebrospinal total protein upper reference values.

Bourque PR, Brooks J, Warman-Chardon J, Hegen H, Deisenhammer F, McCudden CR, Breiner A.

Data Brief. 2019 Mar 7;23:103760. doi: 10.1016/j.dib.2019.103760. eCollection 2019 Apr.

11.

Conversion and reversion of anti-John Cunningham virus antibody serostatus: A prospective study.

Auer M, Hegen H, Sellner J, Oppermann K, Bsteh G, Di Pauli F, Berger T, Deisenhammer F.

Brain Behav. 2019 Jul;9(7):e01332. doi: 10.1002/brb3.1332. Epub 2019 Jun 6.

12.

Free light chains in the cerebrospinal fluid. Comparison of different methods to determine intrathecal synthesis.

Hegen H, Walde J, Milosavljevic D, Aboulenein-Djamshidian F, Senel M, Tumani H, Deisenhammer F, Presslauer S.

Clin Chem Lab Med. 2019 Sep 25;57(10):1574-1586. doi: 10.1515/cclm-2018-1300.

PMID:
31112501
13.

The Cerebrospinal Fluid in Multiple Sclerosis.

Deisenhammer F, Zetterberg H, Fitzner B, Zettl UK.

Front Immunol. 2019 Apr 12;10:726. doi: 10.3389/fimmu.2019.00726. eCollection 2019. Review.

14.

The clinical significance of single or double bands in cerebrospinal fluid isoelectric focusing. A retrospective study and systematic review.

Hegen H, Zinganell A, Auer M, Deisenhammer F.

PLoS One. 2019 Apr 15;14(4):e0215410. doi: 10.1371/journal.pone.0215410. eCollection 2019.

15.

A Survey of Cerebrospinal Fluid Total Protein Upper Limits in Canada: Time for an Update?

Bourque PR, McCudden CR, Warman-Chardon J, Brooks J, Hegen H, Deisenhammer F, Breiner A.

Can J Neurol Sci. 2019 May;46(3):283-286. doi: 10.1017/cjn.2019.12. Epub 2019 Mar 27.

PMID:
30915935
16.

Impairment of odor discrimination and identification is associated with disability progression and gray matter atrophy of the olfactory system in MS.

Bsteh G, Steiger R, Tuovinen N, Hegen H, Berek K, Wurth S, Auer M, Di Pauli F, Gizewski ER, Deisenhammer F, Berger T, Scherfler C.

Mult Scler. 2019 Mar 21:1352458519838205. doi: 10.1177/1352458519838205. [Epub ahead of print]

PMID:
30895860
17.

Different Interferon Beta Preparations Induce the Same Qualitative Immune Response in Human Skin.

Hermanrud C, van Capel TMM, Auer M, Karrenbauer V, Deisenhammer F, de Jong EC, Fogdell-Hahn A.

J Interferon Cytokine Res. 2019 May;39(5):302-313. doi: 10.1089/jir.2018.0038. Epub 2019 Mar 8.

PMID:
30848986
18.

Adult CSF total protein upper reference limits should be age-partitioned and significantly higher than 0.45 g/L: a systematic review.

Breiner A, Moher D, Brooks J, Cheng W, Hegen H, Deisenhammer F, McCudden CR, Bourque PR.

J Neurol. 2019 Mar;266(3):616-624. doi: 10.1007/s00415-018-09174-z. Epub 2019 Jan 8.

PMID:
30617996
19.

Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.

Walter E, Berger T, Bajer-Kornek B, Deisenhammer F.

J Med Econ. 2019 Mar;22(3):226-237. doi: 10.1080/13696998.2018.1556668. Epub 2018 Dec 21.

PMID:
30522373
20.

Pregnancy and multiple sclerosis in the DMT era: A cohort study in Western Austria.

Bsteh G, Algrang L, Hegen H, Auer M, Wurth S, Di Pauli F, Deisenhammer F, Berger T.

Mult Scler. 2020 Jan;26(1):69-78. doi: 10.1177/1352458518816614. Epub 2018 Dec 3.

PMID:
30507345

Supplemental Content

Loading ...
Support Center